ArticleScientific reports2025
Unveiling nature's antidiabetic potential in Berberis orthobotrys seeds for alloxan-induced diabetic rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeted Regulation of Pancreatic Islet Function by Natural Products Against Type 2 Diabetes Mellitus: Advances and Prospects.Biomolecules · 2026Review
- Effects of Bioactive Microalgal Pigment Intake on Metabolic Parameters, Cecal Distribution and Short-Chain Fatty Acids in a Diabetic Rat Model.Life (Basel, Switzerland) · 2026Article
- Beneficial effects of berberine in the treatment of diabetes and its complications.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
To illustrate the anti-diabetic properties of Berberis orthobotrys seeds was the aim of the current study. After a series of experiments, two doses of aqueous methanolic extract of the seeds were selected i.e., 151 mg/kg and 301 mg/kg to assess the anti-diabetic potential in normoglycemic, alloxan-induced and glucose-loaded diabetic rats. The effect of the seeds extract on total cholesterol and triglycerides was also assessed. Histological examination of the pancreas and the GC-MS analysis of blood and urine samples of rats were also carried out. At 151 mg/kg and 301 mg/kg doses, the aqueous methanolic extracts of Berberis orthobotrys seeds showed promising results for their anti-diabetic potential comparable to Glibenclamide. Studies on the phytochemistry of AMEBO also exposed the existence of alkaloids, steroids, glycosides, flavonoids and resins. Serum lipid measurements showed a substantial reduction in triglycerides and total cholesterol on days 7 and 15. The pancreas's islets were protected by the extract, as shown by a histological analysis. The primary metabolite Berberine, which was qualitatively detected by GC-MS in blood and urine samples of rats, may be the alkaloid in command of insulin release or recovery of beta cells after alloxan destruction. More study is necessary to comprehend the underlying signaling process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.